Scancell Holdings (LSE:SCLP) has successfully raised approximately £15.7 million in gross proceeds after completing an oversubscribed retail offer alongside a UK placing, strengthening its financial position as it advances its immuno-oncology pipeline. The retail offer, conducted through the Winterflood Retail Access Platform, generated £2.7 million at an issue price of 9 pence per share. Demand exceeded the shares available, resulting in scaled-back allocations with priority given to existing shareholders.
The company has applied for the new shares to be admitted to trading on AIM, with admission expected to take effect on or around 28 July 2026. Following the issue, Scancell’s enlarged share capital will comprise 1,212,230,683 ordinary shares, providing shareholders with an updated denominator for calculating interests under the FCA’s disclosure and transparency rules. The retail offer shares will rank equally with both the placing shares and the company’s existing ordinary shares, while the strong level of investor participation highlights continued market support for Scancell’s immuno-oncology development strategy.
Despite the successful fundraising, the company’s investment outlook continues to be constrained by ongoing financial challenges, including operating losses, cash burn and negative shareholder equity, while negative earnings also limit valuation support. These factors are partly balanced by encouraging momentum across the company’s clinical and regulatory programmes, including a clearly defined pathway towards Phase III development. Technical indicators remain positive overall, although the shares appear heavily overbought, suggesting elevated short-term volatility following the recent rally.
More about Scancell Holdings plc
Scancell Holdings plc is a late-stage clinical immuno-oncology company focused on developing innovative cancer immunotherapies designed to stimulate the body’s immune system to recognise and destroy tumour cells. Listed on AIM, the company is advancing a portfolio of treatments targeting difficult-to-treat solid tumours through multiple proprietary immunotherapy platforms.
The company’s strategy centres on developing active immunotherapies that generate durable anti-tumour immune responses, with the aim of improving patient outcomes across a range of oncology indications. As its clinical programmes progress, Scancell continues to focus on advancing candidates through late-stage development while expanding the potential commercial opportunities for its technology platforms.
Leave a Reply